Propanc Biopharma, INC

Propanc Biopharma, Inc. announced the retirement of Annie Van Broekhoven from its Board of Directors and the appointment of Carlo Campiciano, a seasoned accountant with extensive experience in capital raising and financial strategy.

Propanc Biopharma, Inc. announced the appointment of Dr. Ralf Brandt, a seasoned pharmaceutical and oncology research executive, to its Board of Directors following Dr. Julian Kenyon's retirement.

Propanc Biopharma, Inc. received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Propanc Biopharma, Inc. completed a private placement with Hexstone Capital LLC, raising $1,000,099 through the sale of Series C Preferred Stock and a Warrant.

Propanc Biopharma, Inc. entered into a Securities Purchase Agreement with Hexstone Capital LLC for a private placement of Series C Preferred Stock and Warrants to fund general corporate purposes.

Propanc Biopharma, Inc. successfully closed its $4 million public offering and uplisted its common stock to the Nasdaq Capital Market under the symbol PPCB.

Propanc Biopharma reports a net loss of $6.36 million for the third quarter of fiscal 2026 as it continues development of its lead cancer treatment candidate, PRP.

Propanc Biopharma, Inc. reported a significant net loss of $7.9 million for the six months ended December 31, 2025, as it continues preclinical development of its cancer treatment candidate, PRP, and addresses going concern issues.

Propanc Biopharma posted a significant net loss in Q1 2026, driven by higher administrative costs, despite a successful Nasdaq listing and new patent grant.

Propanc Biopharma reports its Q3 2025 results, highlighting ongoing research and development efforts and the need for additional financing.

Propanc Biopharma reports ongoing losses for the quarter ended December 31, 2024, while implementing a reverse stock split to address listing requirements.

Propanc Biopharma's Q1 2025 report reveals ongoing financial struggles, including a net loss and a working capital deficit, alongside plans for a reverse stock split and a potential NASDAQ uplisting.

Propanc Biopharma, a biopharmaceutical company, reported a significant increase in net loss to $58.9 million for fiscal year 2025, driven by substantial stock-based compensation, while advancing its lead cancer drug candidate, PRP, towards Phase Ib clinical trials.

Propanc Biopharma, a biopharmaceutical company focused on cancer treatments, released its fiscal year 2024 results and detailed its plans for upcoming clinical trials.

Propanc Biopharma, Inc. announced a private placement of Series C Preferred Stock and Warrants to Hexstone Capital LLC, approved by majority stockholder consent.

Propanc Biopharma is set to execute a reverse stock split at a ratio between 1:10,000 and 1:100,000, approved by a majority stockholder, to improve its financing and capital raising ability.

Propanc Biopharma, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 2.5 million shares of its common stock.

Propanc Biopharma, Inc. has filed an S-1 registration statement to allow for the resale of up to 15,000,000 shares of its common stock by Hexstone Capital LLC.

Propanc Biopharma, a development-stage cancer treatment company, reported significant losses and a going concern warning, despite recent patent filings and capital raises.

Propanc Biopharma, a development-stage healthcare company, filed an S-1 registration statement for the resale of up to 7,000,000 shares of common stock by a selling stockholder, with its stock trading at $0.39 per share on Nasdaq.

Propanc Biopharma, a development-stage oncology company, reported substantial net losses and negative cash flows, raising significant doubt about its ability to continue as a going concern, despite recent capital raises.

Propanc Biopharma, a development-stage oncology company, is seeking to raise $4.6 million through a public offering of 1 million common shares at $5.00 per share and list on Nasdaq, despite reporting a $54.85 million net loss for the nine months ended March 31, 2025, and facing substantial doubt about its ability to continue as a going concern.

Ionic Ventures, LLC and its affiliates have filed an amendment to their Schedule 13G, indicating they no longer beneficially own more than 5% of Propanc Biopharma, Inc.'s common stock.

Ionic Ventures, along with Ionic Management, Brendan O'Neil, and Keith Coulston, has disclosed a 9.9% beneficial ownership stake in Propanc Biopharma, Inc. through a Schedule 13G filing.